Abstract
Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a serious complication of immunosuppression, particularly after transplantation. Treatment by reduction of immunosuppression risks graft loss after solid organ transplantation (SOT) and only 25-50% of patients respond.
Original language | English |
---|---|
Pages (from-to) | e356-e359 |
Number of pages | 4 |
Journal | Haematologica |
Volume | 104 |
Issue number | 8 |
Early online date | 21 Feb 2019 |
DOIs | |
Publication status | Published - Aug 2019 |
Bibliographical note
The authors would like to thank the Wellcome Trust for funding the initial set up of this bank, and the blood donors from New Zealand who provided cells.Keywords
- T-CELL THERAPY
- DISORDER
- RISK
- MANAGEMENT
- RECIPIENTS